GlassScriptPhysician profile
Mukesh Gopalakrishnan
NPI 1326350562
$10,857.87
in general payments reported to CMS, 2019-2025
39 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,045 · 2020: $1,220 · 2021: $1,112 · 2022: $1,480 · 2023: $1,371 · 2024: $954 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,000.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,791.19 | 2019-2025 | Impella |
| Biotronik INC. | $1,536.19 | 2019-2025 | Biomonitor |
| Novartis Pharmaceuticals Corporation | $1,364.46 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,185.86 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $628.75 | 2019-2025 | Watchman Access System, General - Ep, General - Stents |
| Cvrx, INC. | $513.11 | 2020-2025 | Barostim Neo System |
| Pfizer INC. | $464.43 | 2019-2025 | |
| Abbott Laboratories | $385.40 | 2019-2022 | |
| Zoll Respicardia, INC. | $357.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $342.45 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.54 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $205.00 | 2019-2022 | |
| Amgen INC. | $199.52 | 2020-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $177.93 | 2019-2024 | Eliquis |
| Medtronic, INC. | $170.01 | 2023 | Onyx Frontier |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $165.19 | 2019-2025 | Farxiga, Lokelma |
| Philips North America LLC | $157.95 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $126.19 | 2021-2023 | Optimizer |
| Kestra Medical Technology Services, INC. | $112.98 | 2022-2025 | Assure Wcd |
| Edwards Lifesciences Corporation | $92.86 | 2023-2025 | Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Alnylam Pharmaceuticals INC. | $77.37 | 2022-2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $61.19 | 2022-2025 | |
| Esperion Therapeutics, INC. | $47.95 | 2020-2022 | |
| Cardiovascular Systems INC. | $47.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $43.10 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $41.21 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $41.12 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $38.87 | 2022-2023 | Opsumit, Uptravi |
| Acacia Pharma INC | $33.22 | 2021 | |
| Terumo Medical Corporation | $31.27 | 2022 | |
| Medtronic Vascular, INC. | $28.80 | 2020 | |
| Astellas Pharma US INC | $27.21 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $21.89 | 2023 | Inpefa |
| Shockwave Medical, INC | $19.37 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Tactile Systems Technology INC | $18.37 | 2023 | Flexitouch Plus, Entre Plus |
| Regeneron Healthcare Solutions, INC. | $16.04 | 2019 | |
| Smith+Nephew, INC. | $14.50 | 2025 | Pico 7 |
| Chiesi USA, INC. | $11.89 | 2021 | |
| Cook Medical LLC | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Gopalakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.